Telix and United Imaging Announce Strategic Theranostics Collaboration

Melbourne (Australia) and Indianapolis, IN and Houston, TX (United States) | June 2, 2026

  • Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.

  • Initial focus on TLX101-Px (Pixclara®[1], Floretyrosine F 18) in the U.S.

  • Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.

Telix and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing integrated theranostics solutions.

The companies will evaluate the combination of United Imaging’s scanner platforms, software, connectivity and AI capabilities with Telix’s molecular imaging portfolio and validated clinical protocols. The collaboration will explore how a unified approach can drive theranostic workflow efficiencies and standardization by:

  • Enhancing integration between imaging systems and radiopharmaceutical workflows.
  • Enabling consistent, protocol-driven imaging performance across systems and sites.
  • Supporting treatment planning, monitoring, and longitudinal patient management.
  • Advancing data-driven and AI-enabled clinical decision support tools.

Jeffrey M. Bundy, Ph.D., President & Chief Commercial Officer, United Imaging Healthcare North America, said, “Theranostics represents a fundamental shift toward more integrated and personalized cancer care. Through this collaboration with Telix, we aim to explore how deeply integrated imaging, AI, and radiopharmaceutical workflows can be combined to support routine clinical use at scale.”

Kevin Richardson, CEO, Telix Precision Medicine, added, “Realizing the full potential of theranostics requires close alignment between state-of-the-art scanners, integrated software solutions, and radiopharmaceutical innovation. By working with United Imaging, we are exploring new ways to deliver more seamless, data-driven workflow solutions that can support clinicians in their decision making, leading to better patient outcomes.”

The collaboration will initially focus on TLX101-Px (Pixclara®1, Floretyrosine F 18) in the U.S, with potential expansion into additional markets, and other Telix products and product candidates, subject to mutual agreement. Early efforts will include scanning protocol optimization, workflow support tools development and validation, and launching pilot programs aligned with high-impact clinical applications.

TLX101-Px has not received a marketing authorization in any jurisdiction.

[1] Brand name subject to final regulatory approval.